Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugates for ADC
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan is a linker utilized for the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic agents to target antibodies, enhancing selective delivery to tumor cells. ADCs synthesized with Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan demonstrate significant antitumor efficacy both in vitro and in vivo, making it a valuable reagent for cancer research and therapeutic applications. -
Drug-Linker Conjugates for ADC
Fmoc-Gly-Gly-Phe-Gly-Paclitaxel is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound combines the Fmoc-Gly-Gly-Phe-OH linker with the potent tubulin polymerization inhibitor, Paclitaxel, facilitating targeted delivery in cancer research. Its unique structure enables the selective treatment of tumor cells, making it a valuable tool for studying ADC efficacy and mechanisms in oncology. -
Drug-linker Conjugate for ADC
DMBA-SIL-Mal-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent antitumor cytotoxin monomethyl auristatin E (MMAE), a tubulin inhibitor. This compound provides targeted delivery of MMAE to cancer cells via a stable linkage with DMBA-SIL-Mal, enhancing its therapeutic efficacy. It serves as a valuable tool for researchers investigating ADCs in cancer therapy and drug development. -
Drug-Linker Conjugates for ADC
ADC-VI is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), utilizing Deruxtecan as the cytotoxic agent. This compound facilitates targeted delivery by chemically linking Tricyclene to an anti-FGFR2b antibody through a conjugation reaction. ADC-VI is primarily employed in research applications focused on enhancing the efficacy and selectivity of cancer therapeutics, particularly in tumors expressing FGFR2b. -
Drug-Linker Conjugate for ADC
STING agonist-49-CO-C2-mal is a non-cleavable drug-linker conjugate designed for antibody-drug conjugates (ADCs) targeting the STING pathway. This compound serves as a crucial component in the synthesis of ADCs, enabling targeted delivery of cytotoxic agents to enhance therapeutic efficacy in cancer research. With its dual functionality—acting as both a target protein ligand and an E3 ligase ligand—STING agonist-49-CO-C2-mal facilitates the development of innovative cancer therapies through precise modulation of immune responses. -
Drug-Linker Conjugates for ADC
Tismanitin maleimide functions as a linker-cargo component in antibody-drug conjugates (ADCs). It enables the covalent attachment of monoclonal antibodies (mAbs) through a cleavable linker, thereby facilitating targeted anti-cancer therapies. This reagent is particularly valuable for research applications focused on multiple myeloma. -
Drug-Linker Conjugate for ADC
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a quinoline-based payload that acts as a nicotinamide adenine dinucleotide (NAD+) biosynthesis inhibitor, specifically targeting NAMPT. It is suitable for research focused on developing ADCs for targeted cancer therapies, enhancing selective cytotoxicity while minimizing effects on healthy tissues. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing off-target effects. It is ideal for research applications in cancer therapy and drug development, particularly in optimizing ADC formulations. -
Drug-Linker Conjugate for ADC
STING agonist-49-PAB-Ala-Val-CO-C2-mal is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This compound functions as a pep-cSTING linker-payload, promoting the activation of the STING pathway to enhance therapeutic efficacy. Its applications include facilitating targeted delivery of cytotoxic agents to enhance anti-tumor immunity and investigating the role of STING in immune modulation. This versatile agent is instrumental for research in targeted therapeutics and immune-related studies. -
Drug-linker Conjugate for ADC
MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing efficacy while minimizing systemic toxicity. Its applications extend to cancer research and the investigation of autoimmune diseases, contributing to the development of innovative therapeutic strategies. -
Drug-Linker Conjugate for ADC
Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This molecule features the potent antitumor agent Calicheamicin, linked via a novel chemical moiety to facilitate selective delivery to tumor cells. It serves as a critical component in the synthesis of ADCs, such as PF-06647263, and is essential for advancing research in targeted cancer therapies. -
Drug-Linker Conjugate for ADC
Glucocorticoid receptor modulator 4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound demonstrates glucocorticoid receptor (GRE) reporter activation in mTNF-expressing K562 cells with an EC50 of 40 μM. Additionally, it exhibits binding affinity with anti-tumor necrosis factor (TNF) antibodies and exhibits anti-inflammatory effects in mouse models of arthritis, making it a valuable tool for research in inflammation and autoimmune diseases. -
Drug-Linker Conjugate for ADC
MC-GGFG-3-Methylenecyclobutyl-Exatecan functions as a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the potent cytotoxic properties of Exatecan with a specialized linker, facilitating targeted delivery of therapeutics to cancer cells. It is invaluable for researchers involved in ADC synthesis and development, contributing to advancements in targeted cancer therapies. -
Drug-linker Conjugate for ADC
P5(PEG12)-VC-PAB-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), targeting the DNA topoisomerase I enzyme. This compound combines the potent antitumor activity of Exatecan with the cleavable linker P5(PEG12)-VC-PAB, providing a targeted approach to cancer therapy. It serves as a valuable tool for research applications focused on tumor treatment and the mechanism of ADC efficacy. -
Drug-Linker Conjugate for ADC
LD-38 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a topoisomerase I inhibitor, Exatecan, with a stable, cleavable linker that enhances hydrophilicity. This compound is ideal for the synthesis of various ADCs, including KA-3123-LD38, and is utilized in research focusing on targeted cancer therapies and drug delivery systems. -
Drug-Linker Conjugates for ADC
Mal-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) formulations. This compound consists of a maleimide linker combined with the cytotoxic agent PNU-159682, exhibiting significant anti-tumor activity. Its applications include enhancing the targeted delivery of therapeutics in cancer research and improving the efficacy of cancer treatment through ADC technology. -
Drug-Linker Conjugates for ADC
Val-Ala-PABC-N(Mesylpropane)-Exatecan is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA topoisomerase I, linked via a cleavable Val-Ala-PABC-N(Mesylpropane) moiety. It is intended for research applications focused on targeted cancer therapies, enhancing the selectivity and efficacy of antitumor agents. -
Drug-Linker Conjugates for ADC
DM1-MCC-PEG3-Biotin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound effectively links the potent cytotoxic agent DM1 with biotin via a stable MCC (maleimidocaproic acid) and PEG3 spacer, facilitating targeted delivery of therapeutics by conjugating to biotin-binding antibodies. It is particularly valuable in research focused on developing and optimizing ADCs for cancer treatment, enabling enhanced therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-amide-(3)PEA-PNU-159682 is a drug-linker conjugate designed for targeted antibody-drug conjugate (ADC) applications. This compound features an ADC linker, Mal-Val-Ala-amide-(3)PEA, which is covalently bonded to the cytotoxic agent PNU-159682, exhibiting notable anti-tumor activity. It is suitable for research into cancer therapies, utilizing precise delivery mechanisms to enhance therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate For ADC
LP-6 TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This compound integrates an Eg5 inhibitor with a linker, facilitating targeted drug delivery and enhancing therapeutic efficacy. It is suitable for research applications focused on the development and optimization of ADCs in cancer therapy. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADCs). It employs the potent tubulin inhibitor MMAF, which is covalently linked via the cathepsin-cleavable peptide MC-Val-Cit-PAB. This compound exhibits significant antitumor activity, making it valuable for research applications in cancer therapy and development of targeted drug delivery systems. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-MMAE is a conjugate designed for use in antibody-drug conjugate (ADC) synthesis, incorporating a drug-linker element. The DBCO component facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. The included MMAE moiety, a potent inhibitor of tubulin polymerization derived from dolastatin 10, exhibits significant mitotic inhibition. This reagent is ideal for advancing research in targeted cancer therapies by enabling the precise delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-GGFG-Dxd is a drug-linker conjugate targeting antibody-drug conjugates (ADCs) with potent antitumor activity derived from the DNA topoisomerase I inhibitor Dxd. This compound utilizes a cleavable linker, DBCO-PEG4-GGFG, which enhances selective delivery of the therapeutic agent. DBCO-PEG4-GGFG-Dxd serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it a valuable tool in bioconjugation applications. -
Drug-Linker Conjugate for ADC
MC-VA-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a peptide linker, MC-VA-PAB, with Exatecan, a potent inhibitor of DNA topoisomerase I, to enhance therapeutic efficacy. Synthesis of MC-VA-PAB-Exatecan-based ADCs demonstrates significant antitumor activity, making it a valuable tool for cancer research and drug development. -
Drug-Linker Conjugates for ADC
DL-01 formic is a versatile drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It facilitates the covalent attachment of cytotoxic agents to antibodies, enhancing selective targeting of cancer cells. This reagent plays a crucial role in the development and optimization of ADC formulations for targeted cancer therapies, providing a means to improve therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
PB038 is a drug-linker conjugate featuring a polyethylene glycol (PEG) unit and a cleavable linker connected to Exatecan. This compound is designed to facilitate the targeted delivery of cytotoxic agents in antibody-drug conjugates (ADCs), enhancing therapeutic efficacy while minimizing off-target effects. PB038 is suitable for research applications focused on cancer therapeutics and drug development involving ADC technology. -
Drug-Linker Conjugates for ADC
Mc-VC-PAB-SN38 is a cleavable drug-linker conjugate that combines a linker (Mc-VC-PAB) with the potent DNA topoisomerase I inhibitor SN38. This compound is designed for the synthesis of antibody-drug conjugates (ADCs), providing a targeted approach for delivering therapeutic agents to malignant cells. Its unique structure facilitates the release of SN38 within the cellular environment, enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-betaglucuronide-MMAE-1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound exhibits potent antitumor activity through the action of MMAE, a tubulin polymerization inhibitor. The incorporation of the cleavable ADC linker MC-betaglucuronide enables targeted delivery and release of MMAE in tumor cells, enhancing therapeutic efficacy in cancer research. -
Drug-Linker Conjugate For ADC
MC-VA-PABC-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound integrates the linker peptide MC-VA-PABC with the potent tubulin polymerization inhibitor MMAE, facilitating targeted delivery of the cytotoxic agent. It plays a crucial role in enhancing the therapeutic efficacy of ADCs in cancer research by selectively delivering MMAE to tumor cells while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Gly-Mal-GGFG with the cytotoxic agent Deruxtecan 2-hydroxypropanamide, facilitating targeted delivery of therapeutic agents to cancer cells. It is primarily utilized in research focused on improving the efficacy and specificity of cancer therapies. -
Drug-Linker Conjugates for ADC
AZ14170133 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound comprises a cytotoxic payload, a topoisomerase 1 inhibitor, linked for effective targeted delivery. AZ14170133 is utilized in the synthesis of ADCs such as AZD9592 and AZD8205, making it a valuable tool for cancer research focused on developing innovative therapeutic strategies. -
Drug-Linker Conjugates for ADC
Gly3-VC-PAB-MMAE is a cleavable drug-linker conjugate comprising the linker Gly3-VC-PAB and the potent tubulin inhibitor MMAE. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling targeted delivery of MMAE to cancer cells. Its unique structure allows for the selective release of the cytotoxic agent in the tumor microenvironment, making it valuable in cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
Mal-VC-PAB-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features DM1, a potent microtubule-disrupting agent, linked by the Mal-VC-PAB linker, which enhances targeted delivery to tumor cells. Mal-VC-PAB-DM1 exhibits significant antitumor activity, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that combines a cleavable PEG linker with the potent tubulin polymerization inhibitor MMAF. The DBCO moiety facilitates efficient synthesis through click chemistry, specifically strain-promoted alkyne-azide cycloaddition (SPAAC), allowing for precise conjugation to azide-containing biomolecules. This reagent is essential for enhancing the therapeutic efficacy of ADCs by enabling targeted delivery of cytotoxic agents. -
Drug-linker Conjugate for ADC
NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features a cleavable linker, NH2-PEG3-VC-PAB, which is linked to the potent tubulin inhibitor Monomethyl auristatin E (MMAE). This reagent is essential for facilitating targeted delivery and localized cytotoxicity in cancer research and therapeutic applications. -
Drug-Linker Conjugates for ADC
Mal-PEG8-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker that facilitates selective release of the potent tubulin inhibitor MMAE upon internalization by target cells. It is ideal for research aimed at improving the therapeutic index of ADCs through targeted delivery and enhanced cytotoxicity against cancer cells. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing MMAF as a potent tubulin polymerization inhibitor. The conjugate features a cleavable linker, DBCO-PEG4, which facilitates the selective release of MMAF within target cells. DBCO-PEG4-MMAF serves as a click chemistry reagent, containing a DBCO group that efficiently engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-modified molecules, making it a valuable tool for targeted therapeutics in cancer research. -
Drug-Linker Conjugate for ADC
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, targeting microtubules to exert potent antitumor effects. The compound features the anti-microtubule agent Eribulin, which is covalently linked via the Mal-(CH2)5-Val-Cit-PAB linker. This strategic design enhances the therapeutic efficacy of Eribulin while minimizing systemic toxicity, making it a valuable tool for cancer research and development. -
Drug-Linker Conjugate for ADC
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA Topoisomerase I with an IC50 of 2.2 μM, which interferes with DNA replication and induces apoptosis in cancer cells. Its application in ADCs allows for targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
DBCO-(PEG2-VC-PAB-MMAE)2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, linked to a cleavable DBCO-(PEG2-VC-PAB)2 linker. The DBCO group enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, facilitating targeted delivery of cytotoxic agents. Its application is crucial for research in cancer therapeutics, particularly in enhancing the efficacy and selectivity of ADCs. -
Drug-Linker Conjugates for ADC
Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Mal-PEG4-VC-PAB with the cytotoxic agent DMEA-PNU-159682, which derives from metabolites of nemorubicin (MMDX) processed by liver microsomes. It exhibits strong cytotoxicity, making it suitable for targeted cancer therapies in research focused on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The linker comprises Gly-Gly-Phe-Gly-NH-O-CO, which is attached to Exatecan, a potent inhibitor of DNA topoisomerase I. This compound exhibits significant potential in cancer research, facilitating targeted delivery and enhanced therapeutic efficacy in anticancer treatments. -
Drug-Linker Conjugates for ADC
Doxorubicin-SMCC is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), featuring a non-cleavable linker and the anthracycline antibiotic Doxorubicin. Doxorubicin targets DNA topoisomerase II, interrupting DNA replication and transcription processes, which leads to cell death in rapidly dividing cancer cells. This reagent is valuable for research applications focused on targeted cancer therapies and the development of innovative drug delivery systems. -
Drug-Linker Conjugate For ADC
TCO-PEG4-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker (TCO-PEG4-VC-PA) that facilitates the release of the potent tubulin inhibitor MMAE upon cellular internalization. TCO-PEG4-VC-PAB-MMAE incorporates a TCO group suitable for inverse electron demand Diels-Alder (iEDDA) reactions, enabling highly specific conjugation with tetrazine-containing molecules, thus enhancing therapeutic efficacy in targeted treatments. -
Drug-Linker Conjugates for ADC
MC-EVCit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features the MC-EVCit-PAB linker combined with the potent tubulin polymerization inhibitor MMAE, which contributes to its cytotoxic properties. MC-EVCit-PAB-MMAE is utilized in research applications focused on targeted cancer therapies, enhancing the efficacy of ADCs through selective delivery of the chemotherapeutic agent. -
Drug-Linker Conjugates for ADC
MC-SN38 is a drug-linker conjugate that combines the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for the development of antibody-drug conjugates (ADCs). SN38, a bioactive metabolite of the Topoisomerase I inhibitor Irinotecan, exerts its biological activity by inhibiting DNA synthesis and inducing DNA single-strand breaks. This compound is essential for research into targeted cancer therapies that leverage the specificity of antibodies to deliver cytotoxic agents to tumor cells. -
Drug-Linker Conjugate for ADC
SGD-1910 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes the antitumor antibiotic pyrrolobenzodiazepine (PBD), known for its cytotoxic DNA crosslinking activity, linked through the cleavable peptide MC-Val-Ala. This compound demonstrates significant potential in targeted cancer therapies by allowing for the precise delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE) linked to a DBCO-(PEG)3-VC-PAB structure, facilitating targeted drug delivery in cancer research. As a click chemistry reagent, it utilizes a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it valuable in bioconjugation applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG3-VC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the DBCO-PEG3-VC linker with Exatecan, a potent inhibitor of DNA topoisomerase I. Its structure facilitates targeted delivery of the cytotoxic agent to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Research applications include the development of ADCs for cancer treatment, providing a strategic tool for targeted therapy and molecular oncology studies. -
Drug-Linker Conjugate for ADC
SC-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This molecule features the potent antitumor agent monomethyl auristatin E (MMAE), a tubulin inhibitor that disrupts microtubule dynamics, linked through a cleavable SC-VC-PAB linker. SC-VC-PAB-MMAE demonstrates effective cytotoxicity in targeted cancer therapies, making it a valuable tool for research in oncology and ADC development.
